Development of epitope‐based peptide vaccine against novel coronavirus 2019 (SARS‐COV‐2): Immunoinformatics approach
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Medical Virology"
DOI: 10.1002/jmv.25736
Abstract: Recently, a novel coronavirus (SARS‐COV‐2) emerged which is responsible for the recent outbreak in Wuhan, China. Genetically, it is closely related to SARS‐CoV and MERS‐CoV. The situation is getting worse and worse, therefore, there is… read more here.
Keywords: novel coronavirus; sars cov; development epitope; peptide vaccine ... See more keywords
Results of a Phase 1/2 Study in Metastatic Renal Cell Carcinoma Patients Treated with a Patient-specific Adjuvant Multi-peptide Vaccine after Resection of Metastases.
Sign Up to like & getrecommendations! Published in 2017 at "European urology focus"
DOI: 10.1016/j.euf.2017.09.009
Abstract: Treatment of metastatic renal cell carcinoma comprises metastasectomy±systemic medical treatment. Specific immunotherapy after metastasectomy could be a complementary option. In this phase 1/2 study, safety and tolerability of an adjuvant multi-peptide vaccine (UroRCC) after metastasectomy… read more here.
Keywords: peptide vaccine; cell carcinoma; renal cell; metastatic renal ... See more keywords
Role of artificial intelligence in peptide vaccine design against RNA viruses
Sign Up to like & getrecommendations! Published in 2021 at "Informatics in Medicine Unlocked"
DOI: 10.1016/j.imu.2021.100768
Abstract: RNA viruses have high rate of replication and mutation that help them adapt and change according to their environmental conditions. Many viral mutants are the cause of various severe and lethal diseases. Vaccines, on the… read more here.
Keywords: artificial intelligence; peptide vaccine; rna; rna viruses ... See more keywords
Immunoinformatics characterization of SARS-CoV-2 spike glycoprotein for prioritization of epitope based multivalent peptide vaccine
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Molecular Liquids"
DOI: 10.1016/j.molliq.2020.113612
Abstract: Abstract The COVID-19 pandemic caused by SARS-CoV-2 is a public health emergency of international concern and thus calling for the development of effective and safe therapeutics and prophylactics particularly a vaccine to protect against the… read more here.
Keywords: peptide vaccine; sars cov; spike glycoprotein; cov spike ... See more keywords
CoVac501, a self-adjuvanting peptide vaccine conjugated with TLR7 agonists, against SARS-CoV-2 induces protective immunity
Sign Up to like & getrecommendations! Published in 2022 at "Cell Discovery"
DOI: 10.1038/s41421-021-00370-2
Abstract: Safe, effective, and economical vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are needed to achieve adequate herd immunity and end the pandemic. We constructed a novel SARS-CoV-2 vaccine, CoVac501, which is a self-adjuvanting… read more here.
Keywords: sars cov; peptide vaccine; covac501; covac501 self ... See more keywords
In silico analysis for development of epitopes-based peptide vaccine against Alkhurma hemorrhagic fever virus
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Biomolecular Structure and Dynamics"
DOI: 10.1080/07391102.2019.1651673
Abstract: Abstract Alkhurma hemorrhagic fever virus (ALKV) causes a fatal clinical disease in human beings of different tropical and sub-tropical regions. Recently, the ALKV epidemics have raised a great public health concern with the room for… read more here.
Keywords: hemorrhagic fever; fever virus; peptide vaccine; based peptide ... See more keywords
IMMU-31. PNOC007: H3.3K27M SPECIFIC PEPTIDE VACCINE COMBINED WITH POLY-ICLC FOR THE TREATMENT OF NEWLY DIAGNOSED HLA-A2+ H3.3K27M DIFFUSE MIDLINE GLIOMAS (DMG)
Sign Up to like & getrecommendations! Published in 2020 at "Neuro-Oncology"
DOI: 10.1093/neuonc/noaa222.385
Abstract: Abstract OBJECTIVE To assess safety and efficacy within a multi-center trial the H3.3K27M specific peptide vaccine with poly-ICLC in HLA-A02.01+ patients diagnosed with H3.3K27M+ DMGs. METHODS After focal radiation therapy, participants 3–21 years of age… read more here.
Keywords: poly iclc; 3k27m specific; specific peptide; peptide vaccine ... See more keywords
PDCT-17 (LTBK-11). PNOC007: H3.3K27M SPECIFIC PEPTIDE VACCINE COMBINED WITH POLY-ICLC FOR THE TREATMENT OF NEWLY DIAGNOSED HLA-A2+ H3.3K27M MIDLINE GLIOMAS
Sign Up to like & getrecommendations! Published in 2019 at "Neuro-Oncology"
DOI: 10.1093/neuonc/noz219.1200
Abstract: To assess within a multi-center trial the safety of H3.3K27M specific peptide vaccine in combination with poly-ICLC in HLA-A02.01+ patients diagnosed with H3.3K27M+ diffuse midline gliomas. Subjects 3–21 years of age with CLIA confirmed H3.3K27… read more here.
Keywords: poly iclc; 3k27m specific; treatment; specific peptide ... See more keywords
A novel recombinant anti‐epidermal growth factor receptor peptide vaccine capable of active immunization and reduction of tumor volume in a mouse model
Sign Up to like & getrecommendations! Published in 2017 at "Microbiology and Immunology"
DOI: 10.1111/1348-0421.12547
Abstract: Over‐expression of epidermal growth factor receptor (EGFR) has been reported in a number of human malignancies. Strong expression of this receptor has been associated with poor survival in many such patients. Active immunizations that elicit… read more here.
Keywords: immunization; peptide vaccine; receptor; vaccine ... See more keywords
Phase 1 study of OCV‐C02, a peptide vaccine consisting of two peptide epitopes for refractory metastatic colorectal cancer
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Science"
DOI: 10.1111/cas.13227
Abstract: OCV‐C02 is a peptide vaccine consisting of two peptide epitopes derived from ring finger protein 43 (RNF43) and translocase of outer mitochondrial membrane 34 (TOMM34). This Phase 1 study assessed the safety, preliminary efficacy and… read more here.
Keywords: consisting two; ocv c02; peptide vaccine; cancer ... See more keywords
Long-term follow-up of anti-PD-1 naïve patients with metastatic melanoma treated with IDO/PD-L1 targeting peptide vaccine and nivolumab
Sign Up to like & getrecommendations! Published in 2023 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2023-006755
Abstract: Background We have previously published initial efficacy of the indoleamine 2,3-dioxygenase (IDO)/anti-programmed death ligand 1 (PD-L1) vaccine in combination with nivolumab in 30 anti-PD-1 therapy naïve patients with metastatic melanoma (cohort A). We now report… read more here.
Keywords: long term; response; term follow; peptide vaccine ... See more keywords